June 6, 2025
June 9, 2025
This week’s newsletter included:
- Recap of Australia Clinical Trials Event
- Rep. Kennedy Highlights Utah’s Life Sciences Industry at Committee Hearing
- Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for MDS
- VETFIRE: bioMerieux Launches Cutting-edge Equine Infectious Respiratory Disease Testing
- Arcutis’ ZORYVE (roflumilast) Topical Foam 0.3% Approved by FDA
- Renalytix Growing Collaboration with New York Kidney & Hypertension Medicine
- CancerVax Launches New StartEngine Fundraising Campaign
- CanverVax’s New Chief Scientific Officer, Dr. George Katibah
- CancerVax Scientists Featured on Cytiva’s Discovery Matters Podcast Discussing Universal Cancer Vaccine Platform
- Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
- Don’t Miss BioUtah’s Exclusive Biosphere Magazine Promotional Opportunity
- University of Utah Founders Day Distinguished Alumni Awards
- Utah Business: Nominations for Innovation Awards Open
Featured New BioUtah Elite Bronze Member: AstraZeneca
Recent News
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
- Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
- Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
- GE HealthCare’s Economic Impact Across Utah
- RefloDx Wins Trans Atlantic Angel Grand Prize
